SENATE-BILL 1818: S.1818 - Prescription Drug Price Relief Act of 2025
AI-Powered Summary
SENATE-BILL 1818 aims to lower prescription drug prices to enhance access to necessary medications, particularly for uninsured or underinsured individuals. The legislation addresses affordability by targeting excessively priced drugs, prioritizing the needs of larger patient populations. It raises constitutional considerations regarding the right to healthcare and property rights of pharmaceutical companies, especially concerning patents. The bill's process for determining excessive prices may invoke due process concerns and could be seen as a 'taking' under the Fifth Amendment, potentially leading to legal challenges related to antitrust laws. Key provisions include the Secretary of Health and Human Services determining excessive prices based on international pricing, allowing open licenses for excessively priced drugs to increase competition, and establishing a public database for price transparency. Manufacturers will be required to report pricing and revenue information, promoting accountability and potentially lowering prices for consumers. The implementation timeline and specific requirements for compliance will be critical in assessing the bill's overall effectiveness and impact on healthcare access.
Demographic Impact Analysis
Summary
Overall Constitutional Implications
SENATE-BILL 1818 has the potential to significantly improve individual rights related to health care access and affordability. By addressing high prescription drug prices, the bill seeks to ensure that essential medications are accessible to a broader demographic, particularly those who are economically disadvantaged or have chronic health conditions.
Key Individual Rights Affected
Positive
- Right to Health Care Access
- Equal Protection under the Law
Negative
- Economic Liberty of Pharmaceutical Companies
Constitutional Provisions Most Relevant
- Fourteenth Amendment (Due Process and Equal Protection Clauses)
- Commerce Clause
- Fifth Amendment (Takings Clause)
Potential Constitutional Challenges Or Support
While the bill supports individual rights by potentially lowering drug prices, it may face legal challenges from pharmaceutical companies regarding economic liberties and property rights. The balance between public health interests and private economic rights will be a critical area of contention.
Summary Of Bill Implications
The bill aims to make prescription drugs more affordable, which could significantly benefit individuals across various demographic groups, particularly those with lower incomes or chronic health conditions. It is essential to monitor the implementation of the bill to ensure that it does not inadvertently create disparities in access to medications among different demographic groups. Overall, the bill represents a positive step toward enhancing individual rights related to health care access.
Constitutional Analysis
This bill appears to align with constitutional principles. The proposed legislation operates within the established framework of constitutional authority and does not appear to conflict with fundamental rights or the separation of powers.
Analysis generated using AI-powered review of constitutional principles and legal precedents.
Take Action
Text 50409
💡 How to use:
These links will start a conversation with ResistBot. When prompted, mention S. 1818 to reference this bill.
Contact Your Representatives
Write to YOUR elected officials about this bill
Rate This Bill
Sign in to save a private rating for this bill and track your civic engagement over time.
Sign In FreePolicy Topics
Timeline
May 20, 2025
Bill Introduced
Current
Referred to Committee
June 12, 2026
Last Updated
Ask the Constitutional AI About This Bill
Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.
Sign In Free to Chat